Plaintiffs Fear Retaliation In MiraLax Antitrust Suit

Law360, New York (April 22, 2011, 4:10 PM EDT) -- Plaintiffs in a putative antitrust class action accusing Braintree Laboratories Inc. of initiating baseless patent litigation to block a generic version of the laxative MiraLax asked a Delaware federal court Thursday to bar the company from retaliating against them.

Rochester Drug Cooperative Inc., Louisiana Wholesale Drug Co. and Meijer Inc. — which bought MiraLax directly from Braintree at what they claim was an inflated cost — sought an injunction preventing Braintree from its allegedly retaliatory termination of their supplier relationships, pending a final decision on their...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.